DEPARTMENT OF STATE HEALTH SERVICES

CENTRAL OFFICE INSTITUTIONAL REVIEW BOARD REQUEST FOR WAIVER OF CONSENT OR AUTHORIZATION

	Protocol #:
Project Title:	
Please describe the risks to subjects involved in this resany others. Explain why these risks are no more than r	±. •
Please check all that apply: Request a Waiver or Alteration of Consent Require: Request a Waiver of Signed Consent (Complete Parl Request a Waiver of Authorization to Use or Disclosic (Complete Part A & D)	rt C)
Part A:	
1. Please justify why the research can not be practical	oly conducted without the waiver.
2. Please justify that the rights or welfare of subjects waiver.	will not be adversely affected by the

Pa	Part B:		
3.	Please describe any plan to provide subjects with additional pertinent information after study completion, if appropriate: Not applicable		
Pa	rt C:		
4.	Is there any link between the subject and the research other than the consent form? Yes (if YES, go to 6) No		
5.	Describe the plan to seek participants' wishes on whether they would prefer a signed consent form to document their participation and how their preferences will be addressed. (Proceed to Part D, if applicable)		
6.	Describe any procedures used in the study and explain why they would not normally require consent outside of the research context.		
	rt D:		
	List specifically the PHI that will collected or used. Explain why the research can not be done without access to this information.		

8.	Describe the plan to protect identifiers from improper use and disclosure and indicate where PHI will be stored and who will have access (include all entities that may have access, e.g. IRB, sponsors, FDA, etc.)
9.	What will happen to the PHI at the conclusion of the study? Will PHI be destroyed at the end of the study? If the answer above is NO, explain why the data must be retained and for how long, including whether the data is needed for a health or research purpose, legal or institutional requirement, or other reason. Be specific.
\mathbf{W}_{1}	ritten Assurance:
inf the	Principal Investigator, my signature below provides written assurance that identifiable formation will not be reused or disclosed except as required by law; for authorized oversight of research project; or for other research only if that research has been reviewed and approved the IRB with specific attention and approval to the issue of access to this PHI.
	Signature of Principal Investigator Date